特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

欧州の医薬品受託製造市場調査と予測

European Pharmaceutical Contract Manufacturing Market Forecast 2018-2023

発行 Orion Market Research Pvt Ltd 商品コード 770595
出版日 ページ情報 英文
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=107.84円で換算しております。
欧州の医薬品受託製造市場調査と予測 European Pharmaceutical Contract Manufacturing Market Forecast 2018-2023
出版日: 2019年01月10日 ページ情報: 英文
概要

当レポートでは、欧州の医薬品受託製造市場について調査し、市場の動向とセグメント別動向、地域別予測、市場に参入する企業のプロファイルについてまとめています。

第1章 レポートのサマリー

第2章 市場概要と洞察

  • 市場の定義
  • バリューチェーン
  • アナリストの見解と現在の市場動向
  • 法規制

第3章 市場決定因子

  • 促進因子
  • 阻害因子
  • 機会

第4章 市場セグメンテーション

  • 製造プロセスタイプ別市場
    • 無菌製造
    • 非無菌製造
  • 製品別市場
    • OTC医薬品
    • API
    • 用量製剤
      • 固形
      • 液体
      • 注射
    • その他
  • 投与ルート別市場
    • 経口
    • 吸入
    • 非経口
    • その他
  • サービス別市場
    • 研究開発
    • 製造
    • サプライチェーンマネジメントなどの非臨床サービス

第5章 競合環境

  • 主要企業分析
  • 主要戦略分析

第6章 地域別分析

  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他

第7章 企業プロファイル

  • Aenova Group GmbH
  • Aesica Pharmaceuticals Ltd.
  • Almac Group Ltd.
  • Aurena Laboratories AB
  • B. Braun Medical Inc.
  • Beltapharm SPA
  • Bio-Synergy Ltd.
  • Boehringer Ingelheim International GmbH
  • Cenexi SAS
  • Corden Pharma International GmbH
  • Delorbis Pharmaceuticals Ltd.
  • Delpharm SAS
  • Esteve Quimica SA
  • Ever Neuro Pharma GmbH
  • Evonik Industries AG
  • Famar SA
  • Fareva Holding SA
  • Feramed BV
  • Galena Pharma Oy
  • Gebro Pharma GmbH
  • GlaxoSmithKline PLC
  • NextPharma GmbH
  • Novozymes A/S
  • Onyx Scientific Ltd.
  • ProBioGen AG
  • Provet SA
  • Recipharm AB
  • Samedan Ltd.
  • Saneca Pharmaceuticals AS
  • Shire PLC
  • Sopharma AD
  • UAB Biotechpharma
  • Venus Pharma GmbH
  • Wacker Biotech GmbH
図表

List of Tables

  • TABLE # 1 EUROPEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY MANUFACTURING PROCESS TYPE, 2017-2023 ($ MILLION)
  • TABLE # 2 EUROPEAN STERILE MANUFACTURING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
  • TABLE # 3 EUROPEAN NON-STERILE MANUFACTURING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
  • TABLE # 4 EUROPEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2017-2023 ($ MILLION)
  • TABLE # 5 EUROPEAN OTC DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
  • TABLE # 6 EUROPEAN API MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
  • TABLE # 7 EUROPEAN FINISHED DOSAGE FORMULATION MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
  • TABLE # 8 EUROPEAN OTHERS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
  • TABLE # 9 EUROPEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2017-2023 ($ MILLION)
  • TABLE # 10 EUROPEAN ORAL ADMINISTRATION MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
  • TABLE # 11 EUROPEAN INHALED ADMINISTRATION MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
  • TABLE # 12 EUROPEAN PARENTERAL ADMINISTRATION MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
  • TABLE # 13 EUROPEAN OTHERS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
  • TABLE # 14 EUROPEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET RESEARCH AND ANALYSIS BY SERVICE, 2017-2023 ($ MILLION)
  • TABLE # 15 EUROPEAN MANUFACTURING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
  • TABLE # 16 EUROPEAN NON-CLINICAL SERVICE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
  • TABLE # 17 EUROPEAN R&D MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)

List of Figures

  • FIGURE # 1 EUROPEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE BY MANUFACTURING PROCESS TYPE, 2017 VS 2023 (%)
  • FIGURE # 2 EUROPEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE BY PRODUCT TYPE, 2017 VS 2023 (%)
  • FIGURE # 3 EUROPEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE BY ROUTE OF ADMINISTRATION, 2017 VS 2023 (%)
  • FIGURE # 4 EUROPEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE BY SERVICE, 2017 VS 2023 (%)
  • FIGURE # 5 UK EUROPEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 6 FRANCE EUROPEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 7 GERMANY EUROPEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 8 ITALY EUROPEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 9 SPAIN EUROPEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 10 ROE EUROPEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2017-2023 ($ MILLION)
目次
Product Code: OMR2019484

European pharmaceutical contract manufacturing market is growing significantly due to cost-effective production, increased inventory and so forth that are otherwise major concerns for the pharmaceutical manufacturers. In addition, rapid turnaround time to introduce new drugs to the market is also a critical concern for pharmaceutical companies. Therefore, contract manufacturing organizations are emerging as an effective alternative to pharmaceutical companies. The partnership with CDMO (contract development & manufacturing organization) enables pharmaceutical firms to reduce drug development cost and save time for further processes.

Moreover, the major factor supporting the growth of European pharmaceutical contract manufacturing market include soaring European pharmaceutical industry. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), production of pharmaceutical products in Europe has reached $257 billion in 2015 which was approximately 16.4% higher than the production in 2010. This represents the growing demand for pharmaceutical products in the region, which in turn is driving the demand for European CDMO to meet the increasing demand for pharmaceutical products and support in R&D activities. Additionally, significant pharmaceutical R&D spending by European economies, increasing demand for generic drugs and the presence of major players is further contributing towards the market growth. However, issues over quality control and shift towards Asia-Pacific countries such as India and China for pharmaceutical outsourcing are hindering the growth of European pharmaceutical contract manufacturing market. In addition, advances in drug discovery and increasing R&D investment by contract manufacturers are expected to create a significant opportunity for the market in the near future.

Furthermore, European pharmaceutical contract manufacturing market is segmented on the basis of manufacturing process type, product type, route of administration and services. As per manufacturing process type, the market is segmented into sterile manufacturing and non-sterile manufacturing. Based on product type, the market is segmented into over-the-counter (OTC) drugs, active pharmaceutical ingredients, finished dosage formulations and others. Based on the route of administration, the market is segmented into oral administration, inhaled administration, parenteral administration, and others. Based on service, the market is segmented into manufacturing, non-clinical service, and R&D.

European pharmaceutical contract manufacturing market is segmented into countries, such as UK, Germany, Italy, Spain, France and Rest of Europe (RoE). UK and Germany are gaining significant share due to the presence of some major CDMO in these economies such as Boehringer Ingelheim International GmbH and B. Braun Medical Inc. Moreover, France is also showing potential growth during the forecast period due to increasing pharmaceutical R&D investment in the country.

Some of the key vendors of the European contract manufacturers includes GlaxoSmithKline PLC, B. Braun Medical Inc., Novozymes A/S, Corden Pharma International GmbH and Evonik Industries AG. These companies adopt various strategies such as mergers & acquisitions, geographical expansion, and partnerships to gain significant market share. For instance, In October 2017, CordenPharma acquired Hospira Boulder API facility in the US from Pfizer Inc. With the integration of CordenPharma network with pharmaceutical supply business of Hospira Boulder's shows a unique opportunity to more strengthen leading position of CordenPharma as a CDMO supplier of APIs to the pharmaceutical industry.

Research Methodology

The market study of European pharmaceutical contract manufacturing market is incorporated by extensive primary and secondary research conducted by a research team at OMR. Secondary research has been conducted to refine the available data to break down the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macroeconomic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary Sources Include:

Financial reports of companies involved in the market

Authentic Public Databases.

Whitepapers, research-papers, and news blogs

Company websites and their product catalog

The report is intended for government and private companies for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size and will serve as a source for 360-degree analysis of the market thoroughly integrating different models delivering valuable insights into market for better business decisions.

Market Segmentation-

European Pharmaceutical Contract Manufacturing Market Research and Analysis by Manufacturing Process Type

European Pharmaceutical Contract Manufacturing Market Research and Analysis by Product Type

European Pharmaceutical Contract Manufacturing Market Research and Analysis by Route of Administration

European Pharmaceutical Contract Manufacturing Market Research and Analysis by Service

European Pharmaceutical Contract Manufacturing Market Research and Analysis by Country

The Report Covers:

Comprehensive research methodology of European pharmaceutical contract manufacturing market.

This report also includes a detailed and extensive market overview with key analyst insights.

An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.

Analysis of regional regulations and other government policies impacting the European pharmaceutical contract manufacturing market.

Insights about market determinants which are stimulating the European pharmaceutical contract manufacturing market.

Detailed and extensive market segments with regional distribution of forecasted revenues.

Extensive profiles and recent developments of market players.

Table of Contents

CHAPTER 1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Countries
    • 1.2.3. By Stakeholders

CHAPTER 2. Market Overview and Insights

  • 2.1. Market Definition
  • 2.2. Value Chain of European Pharmaceutical Contract Manufacturing Market
  • 2.3. Analyst Insight & Current Market Trends
    • 2.3.1. Key Findings
    • 2.3.2. Recommendation
    • 2.3.3. Conclusion
  • 2.4. Rules & Regulations

CHAPTER 3. Market Determinants

  • 3.1. Motivators
    • 3.1.1. Significant Pharmaceutical R&D Spending by European Economies
    • 3.1.2. Presence of Major Players in the Region Fuels the Market
    • 3.1.3. Increasing Demand for Generic Drugs in the Region
    • 3.1.4. Growth in European Pharmaceutical Industry Coupled with Significant Per Capita Health Expenditure in the Region
  • 3.2. Restraints
    • 3.2.1. Issues Over Quality Control
    • 3.2.2. Shift Towards Asia-Pacific Economies for Outsourcing Pharmaceuticals Services
  • 3.3. Opportunities
    • 3.3.1. Advances in Drug Discovery
    • 3.3.2. Increasing R&D Investment by Contract Manufacturers

CHAPTER 4. Market Segmentation

  • 4.1. European Pharmaceutical Contract Manufacturing Market by Manufacturing Process Type
    • 4.1.1. Sterile Manufacturing
    • 4.1.2. Non-Sterile Manufacturing
  • 4.2. European Pharmaceutical Contract Manufacturing Market by Product Type
    • 4.2.1. Over-The-Counter (OTC) Drugs
    • 4.2.2. Active Pharmaceutical Ingredients (API)
    • 4.2.3. Finished Dosage Formulation
      • 4.2.3.1. Solid Dose
      • 4.2.3.2. Liquid Dose
      • 4.2.3.3. Injectable Dose
    • 4.2.4. Others (Nutritional Products and Packaging)
  • 4.3. European Pharmaceutical Contract Manufacturing by Route of Administration
    • 4.3.1. Oral Administration
    • 4.3.2. Inhaled Administration
    • 4.3.3. Parenteral Administration
    • 4.3.4. Others (Rectal and Vaginal)
  • 4.4. European Pharmaceutical Contract Manufacturing by Service
    • 4.4.1. R&D
    • 4.4.2. Manufacturing
    • 4.4.3. Non-Clinical Service Such as Supply Chain Management

CHAPTER 5. Competitive Landscape

  • 5.1. Key Company Analysis
  • 5.2. Key Strategy Analysis

CHAPTER 6. Regional Analysis

  • 6.1. Europe
    • 6.1.1. UK
    • 6.1.2. Germany
    • 6.1.3. Italy
    • 6.1.4. Spain
    • 6.1.5. France
    • 6.1.6. RoE

CHAPTER 7. Company Profiles

  • 7.1. Aenova Group GmbH
  • 7.2. Aesica Pharmaceuticals Ltd.
  • 7.3. Almac Group Ltd.
  • 7.4. Aurena Laboratories AB
  • 7.5. B. Braun Medical Inc.
  • 7.6. Beltapharm SPA
  • 7.7. Bio-Synergy Ltd.
  • 7.8. Boehringer Ingelheim International GmbH
  • 7.9. Cenexi SAS
  • 7.10. Corden Pharma International GmbH
  • 7.11. Delorbis Pharmaceuticals Ltd.
  • 7.12. Delpharm SAS
  • 7.13. Esteve Quimica SA
  • 7.14. Ever Neuro Pharma GmbH
  • 7.15. Evonik Industries AG
  • 7.16. Famar SA
  • 7.17. Fareva Holding SA
  • 7.18. Feramed BV
  • 7.19. Galena Pharma Oy
  • 7.20. Gebro Pharma GmbH
  • 7.21. GlaxoSmithKline PLC
  • 7.22. NextPharma GmbH
  • 7.23. Novozymes A/S
  • 7.24. Onyx Scientific Ltd.
  • 7.25. ProBioGen AG
  • 7.26. Provet SA
  • 7.27. Recipharm AB
  • 7.28. Samedan Ltd.
  • 7.29. Saneca Pharmaceuticals AS
  • 7.30. Shire PLC
  • 7.31. Sopharma AD
  • 7.32. UAB Biotechpharma
  • 7.33. Venus Pharma GmbH
  • 7.34. Wacker Biotech GmbH